$332.4 million raised by Attovia; $155.5 million raised by Scribe in Q2 2026
Attovia Therapeutics and Scribe Therapeutics both reported second-quarter results on September 2, 2026, highlighting significant capital raises to fund future clinical trials.
On September 2, 2026, Attovia Therapeutics, Inc. (Nasdaq: ATTO) reported gross proceeds of $332.4 million from an upsized initial public offering. The company stated this capital extends its cash runway to the year 2030. CEO Tao Fu noted preliminary clinical proof of concept for drug ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. Complete Phase 1b data is expected in Q4 2026, with Phase 2 studies planned for H1 2027.
Scribe Therapeutics Inc. (Nasdaq: SCTX) announced approximately $155.5 million in aggregate gross proceeds from its upsized initial public offering and a concurrent private placement with Sanofi. Company officials reported cash, cash equivalents, and marketable securities of $43.0 million as of June 30, 2026. These funds provide funding through the first half of 2029. The company also noted initiation of the first-in-human Phase 1 trial for STX-1150 and secured over $25 million from the California Institute for Regenerative Medicine.
